Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease
AS Abdelhamid, TJ Brown, JS Brainard… - Cochrane Database …, 2018 - cochranelibrary.com
Background Researchers have suggested that omega‐3 polyunsaturated fatty acids from
oily fish (long‐chain omega‐3 (LCn3), including eicosapentaenoic acid (EPA) and …
oily fish (long‐chain omega‐3 (LCn3), including eicosapentaenoic acid (EPA) and …
Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology
BG Nordestgaard - Circulation research, 2016 - Am Heart Assoc
Scientific interest in triglyceride-rich lipoproteins has fluctuated over the past many years,
ranging from beliefs that these lipoproteins cause atherosclerotic cardiovascular disease …
ranging from beliefs that these lipoproteins cause atherosclerotic cardiovascular disease …
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP …
K Kotseva, G De Backer… - European journal of …, 2019 - journals.sagepub.com
Aims The aim of this study was to determine whether the Joint European Societies
guidelines on secondary cardiovascular prevention are followed in everyday practice …
guidelines on secondary cardiovascular prevention are followed in everyday practice …
Efficacy and durability of multifactorial intervention on mortality and MACEs: A randomized clinical trial in type-2 diabetic kidney disease
Background Multiple modifiable risk factors for late complications in patients with diabetic
kidney disease (DKD), including hyperglycemia, hypertension and dyslipidemia, increase …
kidney disease (DKD), including hyperglycemia, hypertension and dyslipidemia, increase …
Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries
Background and aims One of the objectives of the ESC-EORP EUROASPIRE V survey is to
determine how well European guidelines on the management of dyslipidaemias are …
determine how well European guidelines on the management of dyslipidaemias are …
Post-myocardial infarction heart failure
Heart failure (HF) complicating myocardial infarction (MI) is common and may be present at
admission or develop during the hospitalization. Among patients with MI, there is a strong …
admission or develop during the hospitalization. Among patients with MI, there is a strong …
Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research …
K Kotseva, G De Backer, D De Bacquer… - European journal of …, 2021 - academic.oup.com
Abstract Background European Action on Secondary and Primary Prevention by Intervention
to Reduce Events (EUROASPIRE) V in primary care was carried out by the European …
to Reduce Events (EUROASPIRE) V in primary care was carried out by the European …
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and …
European journal of preventive cardiology, 2012 - journals.sagepub.com
Atherosclerotic cardiovascular disease (CVD) is a chronic disorder developing insidiously
throughout life and usually progressing to an advanced stage by the time symptoms occur. It …
throughout life and usually progressing to an advanced stage by the time symptoms occur. It …
EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries
K Kotseva, D Wood, D De Bacquer… - European journal of …, 2016 - journals.sagepub.com
Aims To determine whether the Joint European Societies guidelines on cardiovascular
prevention are being followed in everyday clinical practice of secondary prevention and to …
prevention are being followed in everyday clinical practice of secondary prevention and to …
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
Blood Pressure Lowering Treatment Trialists' … - The Lancet, 2014 - Elsevier
Background We aimed to investigate whether the benefits of blood pressure-lowering drugs
are proportional to baseline cardiovascular risk, to establish whether absolute risk could be …
are proportional to baseline cardiovascular risk, to establish whether absolute risk could be …